CAH Quote, Financials, Valuation and Earnings

Weed has a net margin of 0.92% compared to Cardinal Health's net margin of --. Cardinal Health's return on equity of -- beat Weed's return on equity of --.

Cardinal Health has a consensus price target of $170.87, signalling upside risk potential of 5.21%. On the other hand Weed has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardinal Health has higher upside potential than Weed, analysts believe Cardinal Health is more attractive than Weed.

Cardinal Health has a beta of 0.661, which suggesting that the stock is 33.915% less volatile than S&P 500. In comparison Weed has a beta of 0.654, suggesting its less volatile than the S&P 500 by 34.592%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.25%. Weed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Weed pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Weed quarterly revenues of --. Cardinal Health's net income of $506M is higher than Weed's net income of -$440.5K. Notably, Cardinal Health's price-to-earnings ratio is 25.34x while Weed's PE ratio is 180.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus -- for Weed. Usually stocks with elevated PS ratios are considered overvalued.

Cencora has a net margin of 0.92% compared to Cardinal Health's net margin of 0.95%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 183.42%.

Cardinal Health has a consensus price target of $170.87, signalling upside risk potential of 5.21%. On the other hand Cencora has an analysts' consensus of $321.50 which suggests that it could grow by 9.91%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.661, which suggesting that the stock is 33.915% less volatile than S&P 500. In comparison Cencora has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.394%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.25%. Cencora offers a yield of 0.74% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than Cencora quarterly revenues of $75.5B. Cardinal Health's net income of $506M is lower than Cencora's net income of $717.9M. Notably, Cardinal Health's price-to-earnings ratio is 25.34x while Cencora's PE ratio is 33.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.92% compared to Cardinal Health's net margin of 1.39%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $170.87, signalling upside risk potential of 5.21%. On the other hand McKesson has an analysts' consensus of $758.57 which suggests that it could grow by 5.42%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.661, which suggesting that the stock is 33.915% less volatile than S&P 500. In comparison McKesson has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.324%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.25%. McKesson offers a yield of 0.4% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are smaller than McKesson quarterly revenues of $90.8B. Cardinal Health's net income of $506M is lower than McKesson's net income of $1.3B. Notably, Cardinal Health's price-to-earnings ratio is 25.34x while McKesson's PE ratio is 27.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of 0.92% compared to Cardinal Health's net margin of --. Cardinal Health's return on equity of -- beat Pineapple's return on equity of --.

Cardinal Health has a consensus price target of $170.87, signalling upside risk potential of 5.21%. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Cardinal Health has higher upside potential than Pineapple, analysts believe Cardinal Health is more attractive than Pineapple.

Cardinal Health has a beta of 0.661, which suggesting that the stock is 33.915% less volatile than S&P 500. In comparison Pineapple has a beta of 35.962, suggesting its more volatile than the S&P 500 by 3496.159%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.25%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $54.9B, which are larger than Pineapple quarterly revenues of --. Cardinal Health's net income of $506M is higher than Pineapple's net income of --. Notably, Cardinal Health's price-to-earnings ratio is 25.34x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.18x versus 58.98x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.